DS
BBIO icon

DRW Securities’s BridgeBio Pharma BBIO Stock Holding History

DRW Securities’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14,200
Closed -$244K – 350
2023
Q2 		$244K Sell
14,200
-10,300
-42% -$155K 0.01% 282
2023
Q1 		$406K Buy
+24,500
New +$286K 0.01% 225

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DRW Securities's BBIO Position: Q1 2026 in Review

DRW Securities opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 8,057 shares worth $598K. The stake represents 0.01% of the portfolio and ranks #537 among its holdings. This is a return to the name: DRW Securities previously reported a position in BBIO as recently as Q2 2025.

DRW Securities first reported a position in BBIO in Q2 2025 and has held it in 2 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • DRW Securities held 8,057 shares of BridgeBio Pharma worth $598K as of Q1 2026.
  • BridgeBio Pharma was a new DRW Securities position in Q1 2026.
  • BridgeBio Pharma made up 0.01% of DRW Securities's portfolio in Q1 2026, its #537 holding.
  • DRW Securities first reported a position in BridgeBio Pharma in Q2 2025 and has held it in 2 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.